FY2026 Earnings Forecast for Myomo Issued By HC Wainwright

Myomo, Inc. (NYSEAMERICAN:MYO) – Investment analysts at HC Wainwright boosted their FY2026 EPS estimates for shares of Myomo in a research note issued on Tuesday, November 10th. HC Wainwright analyst S. Lee now forecasts that the company will earn ($0.31) per share for the year, up from their prior forecast of ($0.32). The consensus estimate for Myomo’s current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for Myomo’s Q4 2026 earnings at ($0.04) EPS, Q1 2027 earnings at ($0.04) EPS, Q2 2027 earnings at ($0.03) EPS, Q3 2027 earnings at ($0.03) EPS, Q4 2027 earnings at ($0.02) EPS, FY2027 earnings at ($0.12) EPS, FY2028 earnings at ($0.01) EPS, FY2029 earnings at $0.20 EPS and FY2030 earnings at $0.45 EPS.

Myomo (NYSEAMERICAN:MYO) last posted its quarterly earnings results on Monday, November 9th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.01. Myomo had a negative net margin of 33.14% and a negative return on equity of 183.47%. The company had revenue of $12.33 million for the quarter, compared to analyst estimates of $11.51 million.

Myomo Trading Down 1.6%

Shares of NYSEAMERICAN:MYO opened at $1.25 on Thursday. Myomo has a 1-year low of $0.60 and a 1-year high of $1.89. The company has a debt-to-equity ratio of 4.24, a current ratio of 1.92 and a quick ratio of 2.01. The business’s 50 day moving average is $1.37 and its 200-day moving average is $1.09.

Insider Buying and Selling at Myomo

In related news, insider Harry Kovelman sold 17,250 shares of the company’s stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $1.73, for a total value of $29,842.50. Following the sale, the insider owned 105,983 shares of the company’s stock, valued at $183,350.59. The trade was a 14.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last quarter, insiders have sold 47,738 shares of company stock worth $70,662. 12.14% of the stock is currently owned by insiders.

Key Stories Impacting Myomo

Here are a few of the latest stories about MYO:

• Positive Sentiment: HC Wainwright raised its estimates across 2026–2027, including its FY2027 loss forecast to $0.12 per share from $0.28. It also reduced projected quarterly losses for Q4 2026 and each quarter of 2027. Myomo analyst estimate updates
• Positive Sentiment: The analyst sees improving longer-term profitability, revising FY2028 to a loss of $0.01 per share from $0.18, FY2029 profit to $0.20 from $0.02, and FY2030 profit to $0.45 from $0.26. The upgrades suggest a faster path toward profitability, though those forecasts are several years out. Myomo analyst estimate updates
• Neutral Sentiment: A separate Q3 2026 earnings-call summary is listed, but the provided material contains only its headline and link, not enough detail to assess its implications. Myomo, Inc. Q3 2026 Earnings Call Summary

Myomo Company Profile

Myomo, Inc. is a medical device company that develops and markets wearable robotic braces designed to help individuals with impaired upper-limb function regain movement and perform activities of daily living. Its principal product is the MyoPro, a lightweight, electrically powered orthosis that detects a user’s residual muscle signals and assists movement of the arm and hand. The MyoPro is intended for people affected by neuromuscular disorders and injuries, including stroke, brachial plexus injury, multiple sclerosis, traumatic brain injury and spinal cord injury.